drugset / Trial / NCT05795140

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT05795140

Phase 3 Recruiting 65 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.

Timeline

Start
2024-05-08
Primary completion
2032-07-16
Completion
2032-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Iptacopan Small molecule 200 mg Oral